Journal: Therapeutic Advances in Medical Oncology

Article Title: Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment

doi: 10.1177/1758835920974192

Figure Lengend Snippet: Alteration landscape of the paired tumor tissue biopsies collected before (yellow headings) and after histological transformation (green headings). The numbers in the boxes correspond to the variant allele frequency of the mutation or the gene copy number for amplifications. Samples were analyzed using the Advanta Solid Tumor NGS Library Prep Assay (Fluidigm) and sequenced on a NextSeq platform (Illumina). LC, lung carcinoma.

Article Snippet: Libraries were prepared using the Advanta Solid Tumor NGS Library Prep Assay with the automated Juno TM system on integrated fluidic circuits (LP 8.8.6 IFC) (Fluidigm) following the manufacturer’s procedure.

Techniques: Transformation Assay, Variant Assay, Mutagenesis

Journal: Translational Lung Cancer Research

Article Title: Emergence of a HER2 -amplified clone during disease progression in an ALK -rearranged NSCLC patient treated with ALK-inhibitors: a case report

doi: 10.21037/tlcr.2020.04.03

Figure Lengend Snippet: CNV analysis performed with NGS and ddPCR. (A) Plot of normalized coverage levels is shown. Blue dots correspond to target regions without gene amplification (normal regions), orange dots to potential amplified genes; in particular the arrow indicate HER2 gene amplification; (B) ddPCR confirmation on DNA used for NGS analysis, extracted from tissue biopsy, was performed with CNV Assay for HER2 (dHsaCP1000116) and AP3B1 as recommend reference assay (dHsaCP2500348) with ddPCR QX200 Droplet Reader (Bio-Rad, USA) according to the manufacturer’s protocol; (C) CNV studied in cfDNA retrospectively from disease progression (PD) sample backward. CNV, copy number variation; NGS, next generation sequencing; ddPCR, digital droplet PCR; cfDNA, cell-free DNA.

Article Snippet: DNA was extracted from the liver biopsy and studied by next generation sequencing (NGS) (Solid Tumor Solution, Sophia Genetics, on MiSeq Platform, Illumina, USA).

Techniques: Amplification, CNV Assay, Next-Generation Sequencing

Journal: International Journal of Molecular Sciences

Article Title: PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

doi: 10.3390/ijms22073464

Figure Lengend Snippet: Summary of trials, outcomes and adverse events associated with pan-PI3K inhibitors in various phases of clinical studies.

Article Snippet: Pictilisib in combination with Erlotinib (Erl) in advanced solid tumors [ ] , Completed , Genentech, Inc. , I, NCT00975182 , The combination could be safely administered to these patients ( n = 57), with RP2D being 340 mg Pic (5 days on and 2 days off schedule) and 100 mg Erl. However, this combination demonstrated limited anti-tumor activity. , -.

Techniques: Infection, Activity Assay, Inhibition, Mutagenesis, Expressing, Activation Assay, Blocking Assay, Concentration Assay, Reflux, Amplification

Journal: International Journal of Molecular Sciences

Article Title: PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

doi: 10.3390/ijms22073464

Figure Lengend Snippet: Summary of trials, outcomes and adverse events associated with dual PI3K/mTOR inhibitors in various phases of clinical studies.

Article Snippet: Pictilisib in combination with Erlotinib (Erl) in advanced solid tumors [ ] , Completed , Genentech, Inc. , I, NCT00975182 , The combination could be safely administered to these patients ( n = 57), with RP2D being 340 mg Pic (5 days on and 2 days off schedule) and 100 mg Erl. However, this combination demonstrated limited anti-tumor activity. , -.

Techniques: Activity Assay, Biomarker Assay, Concentration Assay, Mutagenesis, Expressing, Western Blot, Inhibition, Immunohistochemistry

Journal: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Article Title: NCI Alliance for Nanotechnology in Cancer – Catalysing Research and Translation Towards Novel Cancer Diagnostics and Therapeutics

doi: 10.1002/wnan.1570

Figure Lengend Snippet: Table of clinical trials associated with technologies developed by Alliance investigators

Article Snippet: Advanced or metastatic: solid tumors, melanoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, merkel cell carcinoma , Intratumoral AST-008 combined with Pembrolizumab in patients with advanced solid tumors ( {"type":"clinical-trial","attrs":{"text":"NCT03684785","term_id":"NCT03684785"}} NCT03684785 ) , 2018 , 2 , Exicure Inc , Gold core spherical nucleic acid.

Techniques: Modification, Diagnostic Assay, Imaging, Small Interfering RNA